Apellis Pharmaceuticals, Inc.
GPTKB entity
Statements (24)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:biotechnology
|
| gptkbp:CEO |
gptkb:Cedric_Francois
|
| gptkbp:country |
gptkb:United_States
|
| gptkbp:employee_count_(2023) |
~600
|
| gptkbp:focusesOn |
complement system therapies
|
| gptkbp:founded |
2009
|
| gptkbp:founder |
gptkb:Cedric_Francois
Dieter Ringgenberg |
| gptkbp:headquarters_location |
gptkb:Waltham,_Massachusetts,_United_States
|
| https://www.w3.org/2000/01/rdf-schema#label |
Apellis Pharmaceuticals, Inc.
|
| gptkbp:industry |
gptkb:biotechnology
pharmaceuticals |
| gptkbp:notableProduct |
gptkb:Empaveli
gptkb:Syfovre |
| gptkbp:publiclyTraded |
true
|
| gptkbp:specializesIn |
ophthalmology
hematology rare diseases |
| gptkbp:stockExchange |
gptkb:NASDAQ
|
| gptkbp:stockSymbol |
gptkb:APLS
|
| gptkbp:type |
gptkb:public_company
|
| gptkbp:website |
https://apellis.com
|
| gptkbp:bfsParent |
gptkb:NASDAQ:APLS
|
| gptkbp:bfsLayer |
8
|